Lantern Pharma INC 8-K filings

Lantern Pharma announced second quarter 2026 financial results, detailing progress in its oncology drug pipeline, including LP-300 and LP-184, and the establishment of Open Medicine AI as a separate entity.

Lantern Pharma establishes Open-Medicine AI as a separate entity to commercialize its multi-agent AI co-scientist platform, expanding beyond oncology.

Lantern Pharma has closed a $4.4 million registered direct offering and concurrent private placement to fund working capital and general corporate purposes.

Lantern Pharma presented its multi-agentic AI co-scientist platform, withZeta.ai, highlighting its capabilities in rare cancer drug discovery and clinical trial design.

Lantern Pharma announced its Q4 and full-year 2025 financial results, highlighting clinical validation across multiple oncology programs and the commercialization progress of its AI platforms.

Lantern Pharma Inc. announced the demonstration of its initial AI tools and multi-agentic system focused on rare cancers at a company-hosted event.

Lantern Pharma reports strong Q3 2025 results, highlighting successful LP-184 Phase 1a trial completion, FDA guidance for pediatric CNS cancer, and advancements in its RADR AI platform.

Lantern Pharma Inc. held its 2025 Annual Meeting, where stockholders elected six directors, approved a one-time stock option repricing, and ratified EisnerAmper LLP as its independent auditor.

Lantern Pharma reported significant clinical trial progress with complete responses for LP-184 and LP-284, alongside advancements in its AI platform and disciplined financial management.

Lantern Pharma Inc. announced the appointment of Dr. Lee T. Schalop to its Board of Directors and a significant amendment to its bylaws, reducing the stockholder meeting quorum requirement from a majority to one-third of outstanding shares.

Lantern Pharma Inc. has entered into an At-The-Market Sales Agreement with ThinkEquity LLC to potentially sell up to $15.53 million of common stock, providing flexible access to capital.

Lantern Pharma reported its Q1 2025 financial results, highlighting clinical trial advancements, AI platform expansion, and a cash runway extending through at least May 2026.

Lantern Pharma reports year-end 2024 financial results and provides business updates, emphasizing advancements in its AI-driven drug development programs and clinical trial progress.

Lantern Pharma Inc. has extended and amended the employment agreement with its Chief Scientific Officer, Kishor G. Bhatia, adjusting the term, minimum hours, and annual base salary.

Lantern Pharma Inc. held a conference call and live webinar on November 7, 2024, to discuss their financial and operating results for the third quarter ended September 30, 2024.

Lantern Pharma announced positive preliminary results from its Phase 2 Harmonic trial, along with updates on its other clinical programs and Q3 2024 financial results.

Lantern Pharma reported encouraging preliminary results from its Harmonic Phase 2 trial and provided updates on its clinical programs and financial status for the second quarter of 2024.

Lantern Pharma's 2024 Annual Meeting saw the election of five directors, approval of an equity incentive plan amendment, and ratification of the company's auditor.

Lantern Pharma's Board of Directors has amended its bylaws to allow the board to set the number of directors within a range of three to nine.

Lantern Pharma announced its first quarter 2024 financial results and provided updates on its clinical trials and AI platform development.

Lantern Pharma announced its 2023 financial results and highlighted advancements in its AI-powered drug development pipeline, including multiple ongoing clinical trials and platform growth.